Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionTd Asset Management Inc
Latest Disclosed Ownership17,534 shares
Latest Disclosed Value $ 520,935
Td Asset Management Inc ownership in TVTX / Travere Therapeutics, Inc.

On May 11, 2026 - Td Asset Management Inc filed a 13F-HR form disclosing ownership of 17,534 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $520,935 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2025 disclosing 0 shares of Travere Therapeutics, Inc.. The current value of the position is $792,537 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 17,534 17,534 521 0.0002
2025-02-11 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 0 -71,800 -100.00 0 -100.00
2024-11-01 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 71,800 71,800 1,006 0.0009
2018-05-11 2018-03-31 13F RETROPHIN COM 761299106 0 -10,800 -100.00 0 -100.00
2018-02-02 2017-12-31 13F RETROPHIN COM 761299106 10,800 -2,600 -19.40 228 -31.74 0.0003
2017-11-09 2017-09-30 13F RETROPHIN COM 761299106 13,400 0 0.00 334 28.46 0.0005
2017-08-01 2017-06-30 13F RETROPHIN COM 761299106 13,400 -8,200 -37.96 260 -34.84 0.0004
2017-05-05 2017-03-31 13F RETROPHIN COM 761299106 21,600 -3,277 -13.17 399 -15.29 0.0006
2017-02-08 2016-12-31 13F RETROPHIN COM 761299106 24,877 -1,323 -5.05 471 -19.62 0.0008
2016-11-02 2016-09-30 13F RETROPHIN COM 761299106 26,200 5,300 25.36 586 57.53 0.0010
2016-08-04 2016-06-30 13F RETROPHIN COM 761299106 20,900 0 0.00 372 30.53 0.0007
2016-05-05 2016-03-31 13F RETROPHIN COM 761299106 20,900 -1,200 -5.43 285 -33.10 0.0005
2016-02-04 2015-12-31 13F RETROPHIN COM 761299106 22,100 0 0.00 426 -4.91 0.0008
2015-11-12 2015-09-30 13F RETROPHIN COM 761299106 22,100 600 2.79 448 -37.17 0.0009
2015-08-11 2015-06-30 13F RETROPHIN COM 761299106 21,500 0 0.00 713 38.45 0.0013
2015-04-28 2015-03-31 13F RETROPHIN COM 761299106 21,500 21,500 515 0.0009
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.